FDA Widens Expanded Access, Will Accelerated Approval Gray Area Narrow?
Executive Summary
FDA's development of two rules to broaden the use of expanded access programs suggests the agency is continuing to position such programs as alternatives to accelerated approval
You may also be interested in...
FDA’s New Leadership May Be More Amenable To Expanded Access Programs
Patient activists say shift in Iplex case shows that the agency may begin to allow more compassionate use for products in development.
Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule
Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule